{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=20", "query": { "condition": "Neuroectodermal Tumor", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 5013, "total_pages": 502, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T01:14:04.254Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003513", "title": "Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Antineoplaston therapy (Atengenal + Astugenal)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "99 Years", "sex": "ALL", "summary": "6 Months to 99 Years" }, "enrollment_count": 3, "start_date": "1996-12-16", "completion_date": "1999-03-29", "has_results": false, "last_update_posted_date": "2017-09-28", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003513" }, { "nct_id": "NCT03420508", "title": "Treating Patients With Melanoma and ALK Alterations With Ensartinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ensartinib", "type": "DRUG" }, { "name": "ALKATI by Customized Nanostring Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-01-10", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 4, "location_summary": "Middletown, New Jersey • Montvale, New Jersey • East White Plains, New York + 1 more", "locations": [ { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "East White Plains", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03420508" }, { "nct_id": "NCT00313508", "title": "Dendritic Cell Vaccination During Lymphoid Reconstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)" ], "interventions": [ { "name": "Autologous Dendritic Cells (DC)", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Autologous Lymphocyte Infusion (ALI)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 18, "start_date": "2006-02", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2014-02-21", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313508" }, { "nct_id": "NCT00019110", "title": "Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Cancer", "Cervical Cancer", "Esophageal Cancer", "Head and Neck Cancer", "Penile Cancer", "Vulvar Cancer" ], "interventions": [ { "name": "human papillomavirus 16 E7 peptide", "type": "BIOLOGICAL" }, { "name": "synthetic human papillomavirus 16 E6 peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1995-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 6, "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Morristown, New Jersey + 1 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019110" }, { "nct_id": "NCT00505635", "title": "Biochemotherapy With Temozolomide for Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Velban", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Intron-A", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2007-03", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00505635" }, { "nct_id": "NCT03817125", "title": "Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Placebo for antibiotic", "type": "DRUG" }, { "name": "Vancomycin pretreatment", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Matching Placebo for SER-401", "type": "DRUG" }, { "name": "SER-401", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Parker Institute for Cancer Immunotherapy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-01-28", "completion_date": "2022-03-04", "has_results": true, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 7, "location_summary": "Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03817125" }, { "nct_id": "NCT05937776", "title": "Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glioma" ], "interventions": [ { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gadoterate Meglumine", "type": "OTHER" }, { "name": "Contrast-enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2023-12-11", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05937776" }, { "nct_id": "NCT06649591", "title": "Expert Consensus and Artificial Intelligence in Medical Decision Making in Patients with Malignant Brain Tumors", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Brain Tumors" ], "interventions": [ { "name": "Survey", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 225, "start_date": "2017-07-01", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06649591" }, { "nct_id": "NCT02060890", "title": "Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adult Glioblastoma" ], "interventions": [ { "name": "specialized tumor board recommendation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2014-08", "completion_date": "2017-05-10", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02060890" }, { "nct_id": "NCT04242199", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "MSI-H/dMMR Tumors", "Cutaneous Squamous Cell Carcinoma", "Urothelial Carcinoma", "Cervical Cancer", "HepatoCellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Small-cell Lung Cancer", "Mesothelioma", "PD-L1 Amplified Tumor (9p24.1)", "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "INCB099280", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2020-09-04", "completion_date": "2024-11-21", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-24T01:14:04.254Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04242199" } ] }